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The world is experiencing an unprecedented health crisis as a result of the highly infectious novel coronavirus. Even 
economically powerful countries with the best healthcare and technology infrastructure are struggling to contain COVID-19. 
Conventional medicine is racing against time to produce vaccine and repurpose drugs used in other viral diseases. India has 
been using its resources maximally to fight COVID-19. However, it is yet to make full use of one of its major resource, 
namely AYUSH (Ayurveda, Yoga, Unaani, Siddha and Homeopathy) systems. Ayurveda, which occupies a prime position 
in the AYUSH systems, has a huge knowledge base and infrastructure accessible in terms of registered practitioners, 
dispensaries, colleges, hospitals, pharmacies, research centres, etc. It is hence only logical that in a crisis like COVID -19, 
ayurveda is utilised for the public. Considering the vast clinical knowledge and experience available with ayurveda, this 
sector should definitely be an advantage for India. This article will discuss why and how the knowledge base and support 
system of ayurveda sector should be leveraged in trying times as the present one.  
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On 30 January 2020, the World Health 
Organisation (WHO) declared the COronaVIrus 
Disease 2019 (COVID-19) outbreak as a Public 
Health Emergency of International Concern (PHEIC) 
under the International Health Regulations (IHR 
2005)1. On 11 March 2020, the WHO declared 
COVID-19 a global pandemic2. The world is now 
experiencing an unprecedented health crisis as a result 
of the highly infectious novel coronavirus (2019-
nCoV), which has a rapid human-to-human 
transmission3. Even economically powerful countries 
like USA, UK, Italy and Spain, with the best modern 
medicine based health infrastructure and services are 
struggling to contain COVID-19(refs4-6).  
There is thus, an urgent need for development of 
drugs which can either inhibit the virus or improve the 
inherent capacity of body to fight against the infection 
or both7,8. Conventional medicine is racing against 
time to produce vaccine and repurpose drugs used in 
other viral diseases7-9. At the same time, China, the 
first country to be affected by the virus had included 
Traditional Chinese Medicine (TCM) and Tibetan 
Medicine (TM) (which has similarities with 
Ayurveda) in their official treatment protocol and had 
successfully treated more than 85% of their COVID-
19 patients using TCM and TM10-16. The positive 
results have been taken cognisance by WHO, 
who have now taken keen interest in the TCM 
clinical trials17. 
Although India has been using its means 
maximally and optimally to fight COVID-19(refs 18-21), 
it is yet to make full use of one of its major resources, 
namely the AYUSH  (Ayurveda, Yoga, Unani, 
Siddha, Homeopathy and Sowa-Rigpa) sector. Just as 
TCM is an officially recognised system of medicine 
in China, AYUSH is also an officially approved 
sector in India. There is a huge infrastructure 
accessible in terms of registered practitioners, 
dispensaries, colleges, hospitals, pharmacies, research 
centres, etc.22,23 (Fig. 1). It is only logical that in a 
crisis like COVID -19, the system is made useful for 
the public. Considering the vast clinical knowledge 
and experience available with the AYUSH systems, 
this sector should definitely be an advantage for India 
as TCM is for China. The knowledge base and 
support system of AYUSH sector should be used in 
trying times as the present one.  
Ayurveda is one of the more popular and well 
known of the AYUSH systems and is the topic of 
discussion in this article. To many outside the 
AYUSH fraternity, Ayurveda is still suspicious. Some 
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that sterilisation is crucial to the success of any 
surgery. Lack of sterilisation can cause hospital 
induced infections and delayed wound healing among 
other problems. Susruta and other ayurvedic surgeons 
definitely had a clear idea of the methods of 
sterilisation to be adopted routinely to prevent any 
post-surgical complications31,32.  
All the aforementioned information indicates the 
tacit acknowledgment of the role of 
microorganisms/germs in disease by the Ayurvedic 
Vaidyas of yester years. The convention in Ayurveda 
however, is to consider any disease as the result of 
changes happening in the status of tridosha, the three 
regulatory functional principles envisaged in 
Ayurveda.  The diseases caused by microorganisms 
are also understood similarly. In other words, the 
microorganisms cause imbalance in doshas, which in 
turn initiate the disease process. An assault by a 
microorganism shall not be a serious pathological 
event as long as it does not influence the status of 
tridoshas. So, rather than focus on the microbiological 
aetiology, the resultant diseases are considered doshic 
in nature and were managed accordingly. 
Interventional strategies to reverse these imbalances 
were developed, used on patients and documented as 
well. All such clinical information provides the priori 
evidence and justification for using Ayurveda in this 
hour of crisis. 
In COVID-19 (as in any other viral / infectious 
disease), there are two factors to consider - (i) the 
virus itself (the pathogen) (ii) the infected person 
(host). This offers two different strategies to manage 
the resultant disease. Allopathy has an anti-pathogen 
approach by which it contains/incapacitates the virus 
using pharmaceutical agents. Ayurveda would adopt a 
pro-host strategy using a diversity of tactics and 
medicines to help the host fight / keep away the 
pathogen and at the same time manage the already 
manifested clinical symptoms. The strategies of both 
allopathy and Ayurveda are scientific in their own 
rights and have definite roles to play.  
 
Challenge 2 - Absence of validation of Ayurveda’s medicines 
by clinical trial 
Guidelines for clinical evaluation of ASU 
(Ayurveda, Siddha and Unani) are given in Chapter 
IV-A (sections 33-B to 33-N) of the Indian Drugs & 
Cosmetics Act (D&C Act) 1940(ref.33). A Gazette 
notification titled ‘Guidelines for evaluation of ASU 
Drugs & Other Traditional Medicines of India under 
Rule - 170 of Drugs & Cosmetics Rules 1945’, was 
also released by Government of India in December 
2008(ref.34). Section 1A of this document mentions that 
classical ayurvedic formulations, when used for 
indications mentioned in texts, are exempt from 
clinical trials to prove their efficacy. 
Thus, rules pertaining to classical formulations 
with prior-human use do not necessarily follow  
the clinical trial rules laid down for proprietary  
medicines or traditional knowledge-based new drug 
discovery35,36. Moreover, the available methodologies 
for clinical trials (developed for single molecule 
drugs) will not do justice to the multi-modal 
ayurvedic therapeutics, which are comprehensive 
comprising of internal medicines, procedures 
(panchakarma), external applications, diet and 
lifestyle regulations. The psychological aspects of the 
patient are also given due consideration while 
interventions are strategized. In addition, ayurvedic 
formulations are complex mixtures with unique 
administration (anupān- drug vehicle) and dosing 
regimens. Therefore, the current methodologies for 
clinical trials have to be modified for the multi-
factorial approach of ayurvedic management. 
Appropriately designed clinical trials for documenting 
the therapeutic efficacy of ayurvedic interventions in 
toto is necessary. Rigorously and meticulously 
planned pilot or observational studies are the other 
options. 
 
Challenge 3 - Providing evidence of efficacy 
The sections on therapeutics in Ayurvedic texts not 
only showcase the practical translation of the 
theoretical framework of Ayurveda but are also 
compendium of evidence provided by the documented 
clinical observations and efficacy. For example, let us 
look at the 30 chapters on therapeutics elaborated in 
Charaka Samhita. Each chapter provides 
comprehensive information about nidana (causative 
factors), samprāpti (etiopathogenesis), lakshana 
(symptomatology), prognosis and classification of the 
disease before detailing the therapeutics. For instance, 
the chapter on jwara (fever) has the following 
explained37- synonyms of jwara (captures the various 
clinical features and progression of the disease), 
prakruti (nature of the disease, i.e. fever), pravritti 
(origin of the disease), prabhāva (sequel of the 
disease), kārana (causative factors), purvarupa 
(premonitory signs and symptoms), adhisthāna (place 
of manifestation), bala kāla (severity and the time of 
manifestation of the disease), ātma lakshana (cardinal 
features off ever), vidhi bheda (classification of the 




disease), linga (signs and symptoms of each type of 
fever), āma jwara linga (sign and symptoms of 
primary stage of the disease), jirna jwara linga  
(sign and symptoms of chronic stage of the 
disease), evolution of the disease, prognosis of 
different types of fever (curable, incurable types) and 
the required precautions at the initial stage of the 
disease. 
The chapter then continues with the management 
principles, guidelines for diet and lifestyle regimens, 
recipes for dietary and beverage preparations, 
vegetables to avoid, contra-indications for certain 
dietary preparations, aushada (drugs for the treatment 
of the disease), contra-indications for certain 
medicines, kriyakrama (various therapeutic 
procedures), clinical indications for the various 
procedures, contra-indications for some procedures, 
hazards of improperly carried-out procedures, post-
procedure care, vimuktha prashānta chinnha (signs 
and symptoms of cure and remission - both 
separately), precautions required after being cured (to 
prevent recurrence), recurrent fever and reasons for 
the recurrence, and guidelines for management of 
recurrent fever. 
The logical inference and interpretation of the 
systematic detailing of the disease and its 
management with comprehensive clinical details as 
mentioned above lead one to infer that the meticulous 
documentation actually provides evidence of 
treatment efficacy in patients afflicted with the 
disease. These classical management principles, 
procedures and formulations are still being used for 
treatment of various diseases thereby generating 
evidence currently and continuously. What is required 
is accurate documentation and compilation (as 
Charaka and Susruta and other Acharyas had done) of 
the present day evidences. 
 
Challenge 4 - Opportunity to generate evidence for COVID-19 
WHO, in its guidance for managing ethical issues 
in infectious disease outbreaks allows for 
“Monitored Emergency use of UnRegistered and 
Experimental Interventions” (MEURI)38. Quoting 
from WHO in this context “There are many 
pathogens for which no proven effective intervention 
exists. For some pathogens there may be 
interventions that have shown promising safety and 
efficacy in the laboratory and in relevant animal 
models but that have not yet been evaluated for 
safety and efficacy in humans. Under normal 
circumstances, such interventions undergo testing in 
clinical trials that are capable of generating reliable 
evidence about safety and efficacy. However, in the 
context of an outbreak characterized by high 
mortality, it can be ethically appropriate to offer 
individual patients experimental interventions on an 
emergency basis outside clinical trials, provided:  
1) no proven effective treatment exists; 2) it is not 
possible to initiate clinical studies immediately;  
3) data providing preliminary support of the 
intervention’s efficacy and safety are available, at 
least from laboratory or animal studies, and use of 
the intervention outside clinical trials has been 
suggested by an appropriately qualified scientific 
advisory committee on the basis of a favourable 
risk–benefit analysis; 4) the relevant country 
authorities, as well as an appropriately qualified 
ethics committee, have approved such use; 5) 
adequate resources are available to ensure that risks 
can be minimized; 6) the patient’s informed consent 
is obtained; and 7) the emergency use of the 
intervention is monitored and the results are 
documented and shared in a timely manner with the 
wider medical and scientific community”. 
The WHO guidelines go onto say “MEURI 
is justified by the ethical principle of respect for 
patient autonomy - i.e. the right of individuals to 
make their own risk-benefit assessments in light of 
their personal values, goals and health conditions. It 
is also supported by the principle of beneficence - 
providing patients with available and reasonable 
opportunities to improve their condition, including 
measures that can plausibly mitigate 
extreme suffering and enhance survival”. Just as 
repurposed allopathic drugs are being used to treat 
COVID-19 using this clause, the same clause can be 
invoked for using the time-tested ayurvedic 
formulations and treatment strategies to treat COVID-
19 positive patients. This aside, the D & C Act of 
India also allows use of classical medicines for 
treatment of patients. However, Government of India 
has declared COVID-19 a notified disease with 
guidelines for its management issued by Ministry of 
Health & Family Welfare (HFW)39. Under these 
circumstances, COVID patients cannot be accessed by 
ayurvedic physicians resulting in their inability to 
generate evidence of the efficacy of Ayurvedic 
management in COVID-19. Table 1 summarises some 
of the challenges faced by Ayurveda and the 
corresponding rejoinders. 




Management of COVID-19: existing knowledge 
that provides Ayurveda the advantage 
2.1. In-context background information 
Ayurveda is a science of life encompassing both 
health and disease. Ayurveda understands health as a 
reflection of the ability of the system to adapt to stress 
(endogenous and exogenous as in COVID-19)40. 
Health exists as a continuum with the environment - 
from soil to plants and animals to human gut and 
other organs. Diseases, except traumatic injuries, are 
considered disruptions arising from within the system. 
Ayurvedic management involves bringing the system 
back to balance. To strategies the therapeutic 
management and risk stratification, Ayurveda has 
several classifications of disease - for example, based 
on clinical symptoms, body constitution (physical, 
physiological and psychological), dosha (underlying 
functional principles), dhātu (tissue elements), season, 
age, digestive capacity, geographical region, 
occupation, etc.  
 Ayurveda has thus, a wide array of principles and 
practices to deal with health and disease. The 
uniqueness of Ayurveda is its theoretical framework 
and its strength is its centuries of accumulated clinical 
expertise41. The clinical practices and the theories 
form the backbone of Ayurveda and have a living 
continuity of practice, documentation and validation 
for over several millennia. In the current context of 
the pandemic, the strength of Ayurveda lies in these 
well validated theories and practices that can be used 
to understand, diagnose and strategise treatments of 
newer diseases like COVID -19.  
‘Diseases are innumerable and newer ones would 
keep appearing’ says Charaka42 and provides methods 
to diagnose and treat new diseases. Ayurveda, with its 
strong theoretical base and extensive pharmacopoeia 
with innumerable drugs, is capable of dealing with a 
wide range of diseases, old or new, known or 
unknown. To bring about cure, Ayurveda identifies 
and treats the disease causing factors (dosha) that are 
inherent to the system but have gone off equilibrium. 
The science of Ayurveda is structured in such a way 
that the very same principles like tridosha that are 
applied in the treatment of known diseases can be 
readily used to treat new and unknown conditions.  
 
Knowledge of epidemics in Ayurveda 
Janapadoddhvamsa [(Janapada - community) + 
(Udhwamsa - destruction)] is the term that denotes 
epidemic in Ayurveda. Charaka Samhita has an entire 
chapter on epidemics detailing the causative factors, 
prevention, line of treatment, etc.43 Ayurveda has a 
well-established and documented management 
strategy during epidemics43. Charaka says. 
“It is not difficult to treat epidemic diseases, 
provided the herbs are collected, preserved and 
administered properly” (Verse 4)  
“Vitiation of factors (air, water, location and 
seasons) lead to the simultaneous manifestations of 
diseases (epidemic) having the same set of symptoms 
leading to the destruction of a country” (Verse 6) 
 
Table 1 — Some of the challenges faced by Ayurveda in the specific context of COVID-19 and the corresponding rejoinders 
1. Lack of germ theory  
in Ayurveda 
 In 1757, Dr. Holwell, a British surgeon had recorded inoculation for smallpox by local 
Ayurvedic Vaidyas (27) 
 Drs. Henderson from Johns Hopkins and Moss from NIH, USA have dated vaccination in India 
prior 1000 AD (28) 
 Susruta, the father of surgery, had used sterilisation to prevent post-surgical infections (31, 32) 
2. Absence of validation 
by clinical trial 
 As per  Drugs & Cosmetics Act Rules, Government of India, classical ayurvedic formulations 
used for indications mentioned in texts are exempt from clinical trials to prove their efficacy 
(34) 
 available methodologies for clinical trials (single drugs) will not suffice for Ayurveda due to the 
multi-factorial and comprehensive approach of Ayurvedic treatment 
 clinical trials for standalone ayurvedic treatments with a comparator arm of standard of care 
(allopathy) is currently not logistically not feasible 
 there are reports of observational and pilot studies, and documentation of the efficacy of 
medicines in certain diseases 
3. Lack of evidence of 
efficacy 
 clinical trials involving comprehensive ayurvedic interventions (in toto) with a standard of care 
control arm is not currently possible to produce the required evidence 
 the detailed clinical information in the sections on therapeutics in the ayurvedic texts are 
evidences of the treatment efficacy observed and documented in days of yore 
4. Lack of opportunity to 
generate evidence for 
COVID-19 
 COVID patients not accessible to ayurveda physicians since COVID-19 has been declared a 
notified disease with guidelines issued by Ministry of Health & Family Welfare, Government of 
India 
 




“One does not suffer from these (epidemic) 
diseases even while all these four vitiated factors (air, 
water, place and season) are at work if he/she is 
administered with medicines and treatment as given 
below ….” (Verses 12-18) 
The knowledge of Ayurveda on management of 
epidemics can definitely be put to use for the current 
pandemic. 
 
Management of fever in Ayurveda 
Fever, the most common hallmark of disease 
known to humans dates back to civilization itself44. 
Diseases and fevers caused by viruses/ pathogens are 
also not new to humans since pathogens have always 
co-existed with cellular life on this planet through 
nearly the entire evolutionary history45. Therefore, 
cold, cough and fever causing viruses and bacteria 
would have been there since time immemorial. It is 
against this background that this section is discussed. 
It is interesting to note the importance given to fever 
in Ayurveda. Infact,the very first disease dealt with in 
Chikitsasthān (section on therapeutics) in Charaka 
Samhita is jwara (fever)37. 
 
अथातोज्वरिचिकित्सतं याख्या यामः||१|| 
इितह माहभगवानातेर्यः||२|| 
 
Translated as ‘We shall now explain the chapter on 
the treatment of jwara (different types of fever), thus 
said Lord Atreya’ (Verses 1-2).  
The chapter covers therapeutics of various 
endogenous and exogenous causes of jwara. It 
discusses management of different types of fevers 
ranging from acute, chronic, continuous, intermittent 
(typical of malaria), seasonal, mild, moderate, severe, 
arising from dhātu (tissue elements) to fevers with or 
without āma (definition follows) and arising from 
one, or combination of two or three doshas. Ama is a 
concept in Ayurveda, which can be best, 
understood as accumulation of toxic metabolic by-
products at various levels of physiology. More 
simply, āma is the by-product of poor digestion and 
according to Ayurveda; it is one of the major factor 
in all diseases. 
Jwara chikitsa (treatment of fever) has been dealt 
with first in the classical texts because Ayurveda 
considers jwara not merely as increase in body 
temperature but also a feeling of malaise involving the 
deha (physical body), indriya (sensory organs) and 
manas (mind) (Verse 4 in ref 37). The imbalance in the 
three doshas manifests not only as increase in body 
temperature and pain but also as inflammation. Jwara 
results from an imbalanced state of pitta, which affects 
digestion and metabolism. Inappropriately digested 
food transforms into āmavisha which Ayurveda 
considers as a predisposing factor for many diseases. 
Jwara is considered the initial manifestation of 
āmavisha in rasa dhātu (all nourishing fluids in the 
body) and if left untreated can lead to other diseases 
according to Ayurveda. Hence, jwara acquires 
importance and requires early intervention before its 
progression to other diseases. The chapter on Jwara 
chikitsa establishes many guiding principles for 
treatment of various diseases described later in the 
section on therapeutics.  
Ayurveda thus has extensive knowledge and 
experience in treating not only various kinds of 
fever37 but also respiratory conditions and cough46,47. 
Ayurveda has many effective strategies (medicines, 
procedures, diet, regimens) for management of the 
clinical conditions (eg. cough, fever, respiratory 
distress) associated with COVID-19. A conservative 
estimate puts the number of time-tested and still in-
use medicines for these conditions in Ayurveda to be 
more than 400(ref.48). There is no dearth of medicines 
in Ayurveda and its use will hence not be a blind 
experiment. Ayurveda can put together an excellent  
treatment  protocol  with  a wide variety of medicines 
for the coronavirus epidemic, which from the typical 
symptoms of fever and respiratory conditions, appear 
to be induced by the predominant involvement of 
kapha and vata doshas.  
 
Knowledge of infectious diseases in Ayurveda 
Considering that virus and other microorganisms 
have always subsisted, long-standing coexistence of 
humans and infectious diseases and the associated 
management challenges would also have always 
existed. Infectious diseases (aupasargika vyādhi) 
were known to ayurvedic vaidyas of yore. The current 
advisory of quarantine, personal hygiene, etc. by 
modern medicine49 is also implied by Susruta in 
Sushruta Samhita50 - 
“Skin diseases, fever, consumption, conjunctivitis 
and all contagious diseases spread from person to 
person, by indulgence in bodily contact, by (coming 
into contact with another’s) breath, eating with others 
in the same plate, sharing of bed and seat, through 
(contact with) clothes, ornaments, and cosmetics”   
Like other diseases in ayurveda, the infectious 
diseases were also understood and addressed in terms 
of dosha, pathogenesis (samprāpti), signs & 




symptoms (lakshanā), the location (sthāna) and 
treatment (chikitsā). For example, in COVID-19, the 
signs and symptoms  of cough, fever and Acute 
Respiratory Distress will be considered to be induced 
predominantly by kapha and vata along with other 
dosha in uras (chest region) (location).The social and 
medical conventions to manage infections in 
Ayurveda are shown in Figure 2. The advisories for 
emotional well-being include the importance of 
righteousness in social life, healthy interpersonal and 
family relations and stress management. 
 
Ayurvedic approach to COVID-19 
For management of COVID-19, Ayurveda will 
adopt a multi-pronged approach based entirely on 
classical, time-tested and documented information in 
Ayurveda (Fig. 3)- (i) therapeutic management 
principles for fever, cough and respiratory distress 
and any other clinical symptoms (ii) management of 
infectious disease, (iii) management during 
epidemics. Ayurveda will therefore adopt a 
comprehensive approach addressing fever, cough, 
respiratory distress and any other symptoms, 
improving the patient’s immunity, improving the 
patient’s emotional / psychological health and 
prescribing the right diet and regimen (customized to 
age, season, occupation and other factors)51-54.  
 
Conclusion 
India is fortunate to have Ayurveda, which has 
perhaps the longest unbroken health tradition in the 
world and for long been the major healthcare system 
in the Indian subcontinent. Ayurveda is now an 
officially approved system of medicine in India. 
Thanks to Government’s investment for the 
establishment and maintenance of ayurvedic facilities, 
there is a huge infrastructure accessible in terms of 
registered practitioners, colleges, hospitals, 
pharmacies, research centres, etc.22,23. The uniqueness 
of Ayurveda is that it is theory-based and not 
empirical. Resting on time tested theories and more 
importantly, unbroken clinical practices dating back 
to several millenia, Ayurveda is one of the most 
systematically codified medical systems in the world. 
While many diseases are described in Ayurvedic 
texts, it also has the wherewithal in terms of theories 
and concepts to diagnose and treat new and unknown 
diseases such as COVID-19.  
In summary, Ayurveda has everything to offer and 
can be of immense use in the management of COVID-
19 crisis.There is nothing to lose but only everything 
to gain by giving Ayurveda the space it deserves in 
the management of COVID-19. Ayurveda should be 
given a chance to deal with this greatest medical 
crisis. This will help bring about an Indian model of 
disease management. Let us remember that COVID-
19 is not the first or the last virus we are seeing and 
falling prey to. It is time to use the accumulated 









Fig. 3 — Factors considered part of treatment strategy. V - vata,
P - pitta, K -kapha; prakruti- biopsychological constitution of an
individual 




documented and passed down over several millennia. 
The knowledge of Ayurveda should benefit the 
suffering Indians and the humanity. If the efforts with 
Ayurveda are scientifically and meticulously planned, 
organized and executed in the larger public interest, 
then one need not be apprehensive and defensive 
about using the time-tested traditional medicine 
against COVID-19. It is the apt time to use the 
knowledge base and support system of Ayurveda for 
the welfare of the masses. 
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